Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Hospital for Special Surgery
New York, NY
Ankylosing spondylitis (AS), the most common spondyloarthropathy, is a chronic, progressive, debilitating inflammatory disease that affects about 1% of adults in the United States. AS often starts in young adulthood and has a substantial negative impact on physical functioning and quality of life. This activity will examine considerations for early recognition and guideline-driven treatment.
Rheumatology and primary care physicians, PAs, and NPs, and other clinicians who encounter patients with AS.
Upon completion of this educational activity, the participant should be able to:
- Describe the evaluation of patients who may have ankylosing spondylitis.
- Employ guideline recommendations for the management of ankylosing spondylitis.
- Describe agents in late-stage development for ankylosing spondylitis.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Dr. Gibofsky discloses the following relationships.
Consultant: AbbVie, Celgene, Flexion, Lilly, Merck, Novartis, Pfizer, Samumed
Speakers Bureau: AbbVie, Celgene, Flexion, Lily, Merck, Novartis, Pfizer, Relburn, Samumed, Sandoz
Stock Ownership (faculty and spouse): AbbVie, Amgen, BMS, J&J, Pfizer, Regeneron
The PIM planners and managers have nothing to disclose. The MCM Education planners and managers have nothing to disclose.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MCM Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions, please contact the accredited provider: www.pimed.com.
Commercial Support Statements
This activity is supported by an independent educational grant from AbbVie.
Estimated time to complete the activity: 30 minutes
- During the period July 10, 2019 through July 10, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
- If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon successfully completing the post-test with a score of 80% or better and the activity evaluation, your certificate will be made available immediately.
CMEcorner.com activities can be viewed on latest versions of Mozilla Firefox, Safari, Google Chrome and Microsoft Edge. On mobile devices, activities are available for iPhone and iPad devices running iOS 10.0 or higher and Android handsets & tablets running Android 7 or higher. Unlimited data plans are recommended.
There are no fees for participating and receiving CME credit for this activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.